Literature DB >> 26618609

Tissue inhibitor of metalloproteinases-4 (TIMP-4) regulates stemness in cervical cancer cells.

Floria Lizarraga1, Magali Espinosa2, Gisela Ceballos-Cancino2, Karla Vazquez-Santillan1, Ivan Bahena-Ocampo2, Angela Schwarz-Cruz Y Celis2, Montserrat Vega-Gordillo2, Patricia Garcia Lopez3, Vilma Maldonado1, Jorge Melendez-Zajgla2.   

Abstract

Tissue inhibitor of metalloproteinase-4 (TIMP-4) belongs to a family of extracellular matrix (ECM) metalloproteinases inhibitors that are overexpressed in several cancers. However, the role of TIMP-4 during carcinogenesis is poorly understood. To evaluate TIMP-4 functions in carcinogenesis, stably transfected cells overexpressing this tissue inhibitor were used. Xenograft tumor growth, stem cell enrichment, colony formation, and gene regulation were investigated. Microarrays and in silico analysis were carried out to elucidate TIMP-4 molecular mechanisms. In the present report, we show that in nude mice, cervical cancer cells that overexpress TIMP-4 formed tumors faster than control cell-derived tumors. Furthermore, in vivo limiting dilution assays showed that fewer TIMP-4 overexpressing cells are needed for tumor formation. In vitro analyses demonstrated that TIMP-4 overexpression or exposure to human recombinant TIMP-4 (hrTIMP4) caused an enrichment of the tumor progenitor cell (TPC) population. Accordingly, genome-wide expression and signaling pathway analyses showed that hrTIMP-4 modulated cell survival, cell proliferation, inflammation, and epithelial-mesenchymal transition (EMT) signaling networks. Notably, NFκB signaling pathway appeared to be globally activated upon hrTIMP-4 treatment. Overall, this report provides the first example that TIMP-4 regulates carcinogenesis through enriching the TPC population in cervical cancer cells. Understanding TIMP-4 effects on tumorigenesis may provide clues for future therapies design.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  NFκB; TIMP-4; gene regulation; tumor progenitor cells

Mesh:

Substances:

Year:  2015        PMID: 26618609     DOI: 10.1002/mc.22442

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

Review 1.  Lysyl Oxidase Family Enzymes and Their Role in Tumor Progression.

Authors:  Tanya Liburkin-Dan; Shira Toledano; Gera Neufeld
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

2.  Remodeling Factors, Transcription Factors and Angiogenetic Factors in Cholesteatoma in Ontogenetic Aspect.

Authors:  Kristaps Dambergs; Gunta Sumeraga; Māra Pilmane
Journal:  Iran J Otorhinolaryngol       Date:  2022-03

3.  A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning.

Authors:  Chen-Tsung Huang; Chiao-Hui Hsieh; Yen-Jen Oyang; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  iScience       Date:  2018-08-23

4.  Knockdown of BRCC3 exerts an anti‑tumor effect on cervical cancer in vitro.

Authors:  Feifang Zhang; Qun Zhou
Journal:  Mol Med Rep       Date:  2018-09-26       Impact factor: 2.952

5.  Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets.

Authors:  Timothy Hua; Ziwei Zeng; Junji Chen; Yu Xue; Yan Li; Qingxiang Sang
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

Review 6.  The Repertoire of Tissue Inhibitors of Metalloproteases: Evolution, Regulation of Extracellular Matrix Proteolysis, Engineering and Therapeutic Challenges.

Authors:  Salvatore Costa; Maria Antonietta Ragusa; Gabriele Lo Buglio; Simone Dario Scilabra; Aldo Nicosia
Journal:  Life (Basel)       Date:  2022-07-28

7.  Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4.

Authors:  Qun Xu; Jinyou Li; Yue Wu; Wenjing Zhou; Zherong Xu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.